TY - JOUR
T1 - Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma
AU - Forrest, D. L.
AU - Thompson, K.
AU - Nevill, T. J.
AU - Couban, S.
AU - Fernandez, L. A.V.
PY - 2002
Y1 - 2002
N2 - Between 1993 and 2000, 24 patients with follicular lymphoma underwent high-dose chemo/radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). Median age was 44 years, median interval from diagnosis to HSCT was 24 months and the median number of prior lines of treatment was three. Donor source was HLA matched sibling (23) or matched unrelated donor (one). Conditioning therapy was busulfan based in 22 patients and included total body irradiation in two. All patients received i.v. cyclosporine A and short-course methotrexate for GVHD prophylaxis. Nineteen patients are alive, a median of 2.3 years post HSCT. Death occurred due to transplant complications in four patients and one patient died of a stroke 10 months post HSCT. No patients have relapsed. The overall and progression-free survival was 78% (95% CI 63-97). Allogeneic HSCT for patients with progressive follicular lymphoma is feasible and may result in prolonged disease-free survival.
AB - Between 1993 and 2000, 24 patients with follicular lymphoma underwent high-dose chemo/radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). Median age was 44 years, median interval from diagnosis to HSCT was 24 months and the median number of prior lines of treatment was three. Donor source was HLA matched sibling (23) or matched unrelated donor (one). Conditioning therapy was busulfan based in 22 patients and included total body irradiation in two. All patients received i.v. cyclosporine A and short-course methotrexate for GVHD prophylaxis. Nineteen patients are alive, a median of 2.3 years post HSCT. Death occurred due to transplant complications in four patients and one patient died of a stroke 10 months post HSCT. No patients have relapsed. The overall and progression-free survival was 78% (95% CI 63-97). Allogeneic HSCT for patients with progressive follicular lymphoma is feasible and may result in prolonged disease-free survival.
UR - http://www.scopus.com/inward/record.url?scp=0036321753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036321753&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1703573
DO - 10.1038/sj.bmt.1703573
M3 - Article
C2 - 12098065
AN - SCOPUS:0036321753
SN - 0268-3369
VL - 29
SP - 973
EP - 978
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 12
ER -